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kappa beta (NFκβ) activation regulates chondrogenic differentia-
tion. This study aims to elucidate the role of NFκβ and downstream
inﬂammatory mediators during the early phase of chondrogenesis.
Methods: The chondroprogenitor ATDC5 was differentiated in
presence of NFκβ activating agents LPS and TNFα or with
the NFκβ inhibitors TLCK, sulfasalazine or parthenolide. NFκβ
activation was determined by analyzing nuclear translocation
and expression of NFκβ targets by RT-qPCR and westernblot.
Prostaglandin E2 (PGE2) production in medium was measured
using a speciﬁc ELISA. Cartilage speciﬁc markers were analyzed
by RT-qPCR and western blot. Similar experiments were per-
formed with human bone marrow stem cells (hBMSCs). hBMSCs
were obtained from iliac crest bone marrow aspirate from 5 young,
genetically healthy, individuals.
Results: ATDC5 cells were triggered for chondrogenesis and dur-
ing the very early onset of differentiation upregulation of inﬂam-
matory mediators COX-2 (and PGE2), iNOS (and NO production),
IL-6 and TNFα was detected (1-8 hours). This inﬂammatory-
response peak was preceded by NFκβ nuclear translocation at
30-60 minutes in differentiation, indicating that expression of these
inﬂammatory mediators might be regulated by NFκβ activation.
To investigate the role of NFκβ activation during early chondro-
genesis, NFκβ activation was stimulated by LPS or TNFα. Both
lead to upregulation of inﬂammatory mediators and was accom-
panied by upregulation of Sox9 at early time points and RunX2,
Collagen II and Collagen X late in differentiation. In contrast, inhi-
bition of nuclear translocation of NFκβ by TLCK, sulfasalazine or
parthenolide prevented the upregulation of inﬂammatory media-
tors at early time points in chondrogenesis. Importantly, inhibition
of NFκβ activation also lead to a concentration dependent inhibi-
tion of chondrogenic differentiation, strongly suggesting that NFκβ
activation is an essential step during early chondrogenesis.
To verify these results, hBMSCs were used as an independent sys-
tem for chondrogenic differentiation. In concert with our ﬁndings
in ATDC5 cells, early chondrogenesis of hBMSCs is also accom-
panied with a similar upregulation of inﬂammatory mediators like
COX-2 and chondrogenic transcription factor Sox9.
Conclusions:During the very early onset of chondrogenesis NFκβ
translocates to the nucleus and seems to regulate the expression
of inﬂammatory mediators and the essential chondrogenic tran-
scription factor Sox9. Stimulation of NFκβ lead to an upregulation
of inﬂammatory mediators and enhanced chondrogenic differen-
tiation, whereas inhibition of NFκβ nuclear translocation inhibited
chondrogenesis. Our results point to an essential role for NFκβ
and inﬂammatory mediators during the ﬁrst steps of chondroge-
nesis, which might regulate Sox9 and subsequent expression of
cartilage molecules.
Also, these data show that the effect of NFκβ activation on cartilage
might depend on the status of cartilage development and is
not solely associated with cartilage degeneration. Importantly,
our results might pave the way for alternative strategies in the
optimization of osteochondrogenic progenitor cell based cartilage
repair techniques.
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Purpose: The pathogenesis of osteoarthritis involves both
changes in bone and cartilage. These processes might be coupled
under some instances. The aim of the present investigation was
to investigate bone and cartilage degradation correlations in os-
teoarthritis patients as a function of sex, BMI, Kellgren-Lawrence
score and diurnal variation.
Methods: The study was a phase-I, 2-week, placebo-controlled,
double-blind, double-dummy, randomized, gender-stratiﬁed study
including 73 subjects (37 postmenopausal women and 36 men),
aged 57-75 years. Patients had to have painful OA of at least
one knee with a Kellgren-Lawrence index score of I-III. Subjects
were allocated to one of three treatment arms: 0.6 mg, 0.8 mg
or placebo. Each treatment was given twice-daily for 14 days. For
evaluation of pharmacodynamics, blood samples were collected
immediately prior to dosing and at ½, 1, 2, 4, 6, and 8 hrs after
morning dose and, for the pre-dinner dose, immediately prior to
dosing, and at the intervals of ½, 1, 2, and 4 hrs post-dose.
Urine samples were collected pre-dose, 2, 4, 6, 8, 13, and 15
hours after morning dose. Study parameters were changes in the
bone resorption marker of CTX-I (serum C-terminal telopeptide
of collagen type I) and the cartilage degradation marker, CTX-II
(urine C-terminal telopeptide of collagen type II).
Results: A signiﬁcant difference (p=0.04) in CTX-I between men
and women, and a borderline signiﬁcant difference between men
and women in CTX-II (p=0.06) was found. At baseline, a corre-
lation between CTX-I and KL-score were not found. In contrast
CTX-II levels were signiﬁcantly correlated to increasing KL-score
in both men and women (P=0.007). BMI and CTX-I was nega-
tively correlated r = -0.40 (p=0.002), whereas CTX-II showed a
weak and non-signiﬁcant positive correlation with BMI, r = 0.25
(p=0.12). No correlation between CTX-I and CTX-II was found
before morning dosing at day 1 and 14. 4 hours after dosing, a
signiﬁcant correlation (r=0.71, p<0.001) between changes in CTX-
I and CTX-II was seen in the sCT group on both day 1 and 14,
whereas in the placebo group a weakly signiﬁcant correlation was
found on day 1 (r=0.49, p=0.02), but not day 14. CTX-I displayed
marked diurnal variation in which a more than 50% decrease was
seen as a response to intake of lunch in the placebo group. CTX-II
displayed lower levels of diurnal variation, indicating that CTX-II
levels also are postprandial regulated.
Conclusions: Bone and cartilage degradation may be coupled
processes. Understanding of the physiological and pathological
situations in which coupling and uncoupling are present may
aid in the identiﬁcation of treatment opportunities for osteoarthri-
tis. We speculate that identiﬁcation of physiological processes in
which both bone and cartilage turnover are attenuated may aid
in the identiﬁcation of new treatment opportunities for osteoarthri-
tis.
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Purpose: To evaluate the expression of 15-lipoxygenase (LOX)-1
and -2 in articular chondrocytes and to investigate the effects of
their metabolites, 13-HODE and 15-HETE, on IL-1-induced MMP-1
and -13 expression.
Methods: The expression of 15-LOX-1 and -2 was analyzed by
reverse transcriptase-polymerase chain reaction (RT-PCR) and
Western blotting in chondrocytes, and by immunohistochemistry in
cartilage. Chondrocytes were stimulated with IL-1 in the absence
or presence of 13-HODE and 15-HETE and the level of MMP-
1 and -13 protein and mRNA expression were evaluated by
immunoassay and real-time RT-PCR, respectively. The role of
